uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted December 7, 2014

FDA Raises Concerns Over Generic ADHD Drugs

On November 13, 2014, the U.S. FDA expressed concerns about whether two approved generic versions of Concerta tablets (methylphenidate hydrochloride extended-release tablets), used to treat attention-deficit hyperactivity disorder in adults and children, are therapeutically equivalent to the brand-name drug. The two approved generic versions of Concerta in question are manufactured by Mallinckrodt Pharmaceuticals and Kudco Ireland Ltd.

An analysis of adverse event reports, an internal FDA re-examination of previously submitted data, and FDA laboratory tests of products manufactured by Mallinckrodt and Kudco have raised concerns that the products may not produce the same therapeutic benefits for some patients as the brand-name product, Concerta, manufactured by Janssen Pharmaceuticals, Inc. (Janssen also manufactures an authorized Concerta generic, which is marketed by Actavis under a licensing agreement and is identical to Janssen's Concerta. FDA included the authorized generic in its analysis and found it to be bioequivalent to, and substitutable for, Concerta.) Apart from the Mallinckrodt, Kudco, and Actavis products, there are no other generics for Concerta.

Methylphenidate hydrochloride extended-release products approved as generics for Concerta are intended to release the drug in the body over a period of 10 to 12 hours. This should allow for a single-dose product that is consistent with the effect of a three times per day dose of immediate-release methylphenidate hydrochloride.

In some individuals, the Mallinckrodt and Kudco products may deliver drug in the body at a slower rate during the 7- to 12-hour range. The diminished release rate may result in patients not having the desired effect.

As a result, the FDA has changed the therapeutic equivalence (TE) rating for the Mallinckrodt and Kudco products from AB to BX. This means the Mallinckrodt and Kudco products are still approved and can be prescribed, but are no longer recommended as automatically substitutable at the pharmacy (or by a pharmacist) for Concerta. identified a similar problem in a generic form of the extended-release antidepressant Wellbutrin XL in 2007, which was eventually removed from the market.

(See's tests of Wellbutrin vs. Generic Bupropion).

You can report a problem with a generic drug to the FDA through its MedWatch program.

You can also report problems with generic drugs to using the link below:

Report a problem with a generic drug

To read the FDA's full statement, use the link below.